Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew S P Sharp

Showing results (71-80 of 106) with videos related to

Pageof 11
Sort By:
Lancet (London, England)|April 7, 2022
Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trialFelix Mahfoud, David E Kandzari, Kazuomi Kario, et al.
JACC. Cardiovascular Interventions|June 22, 2019
Renal Denervation for Treating Hypertension: Current Scientific and Clinical EvidenceMichael A Weber, Felix Mahfoud, Roland E Schmieder, et al.
Journal of the American Heart Association|January 26, 2021
Achieving Optimal Medical Therapy: Insights From the ORBITA TrialMichael Foley, Christopher A Rajkumar, Matthew Shun-Shin, et al.
Circulation|March 19, 2019
Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control After Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO TrialMichel Azizi, Roland E Schmieder, Felix Mahfoud, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|February 15, 2023
Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)Emanuele Barbato, Michel Azizi, Roland E Schmieder, et al.
Journal of Hypertension|September 9, 2024
Aortic reservoir-excess pressure parameters are associated with worse cognitive function in people with untreated stage II/III hypertensionKunihiko Aizawa, Andrew N Jordan, Kim M Gooding, et al.
European Heart Journal|February 15, 2023
Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)Emanuele Barbato, Michel Azizi, Roland E Schmieder, et al.
JAMA Cardiology|November 9, 2022
Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation: Prespecified Analysis at 6 Months of the RADIANCE-HTN TRIO Randomized Clinical TrialMichel Azizi, Felix Mahfoud, Michael A Weber, et al.
Journal of Human Hypertension|May 25, 2021
Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO studyManish Saxena, Roland E Schmieder, Ajay J Kirtane, et al.
Circulation|October 26, 2023
Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial ProgramMichel Azizi, Andrew S P Sharp, Naomi D L Fisher, et al.
Pageof 11

Showing results (71-80 of 106) with videos related to

Sort By:
Pageof 11
Lancet (London, England)|April 7, 2022
Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trialFelix Mahfoud, David E Kandzari, Kazuomi Kario, et al.
JACC. Cardiovascular Interventions|June 22, 2019
Renal Denervation for Treating Hypertension: Current Scientific and Clinical EvidenceMichael A Weber, Felix Mahfoud, Roland E Schmieder, et al.
Journal of the American Heart Association|January 26, 2021
Achieving Optimal Medical Therapy: Insights From the ORBITA TrialMichael Foley, Christopher A Rajkumar, Matthew Shun-Shin, et al.
Circulation|March 19, 2019
Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control After Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO TrialMichel Azizi, Roland E Schmieder, Felix Mahfoud, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|February 15, 2023
Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)Emanuele Barbato, Michel Azizi, Roland E Schmieder, et al.
Journal of Hypertension|September 9, 2024
Aortic reservoir-excess pressure parameters are associated with worse cognitive function in people with untreated stage II/III hypertensionKunihiko Aizawa, Andrew N Jordan, Kim M Gooding, et al.
European Heart Journal|February 15, 2023
Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)Emanuele Barbato, Michel Azizi, Roland E Schmieder, et al.
JAMA Cardiology|November 9, 2022
Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation: Prespecified Analysis at 6 Months of the RADIANCE-HTN TRIO Randomized Clinical TrialMichel Azizi, Felix Mahfoud, Michael A Weber, et al.
Journal of Human Hypertension|May 25, 2021
Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO studyManish Saxena, Roland E Schmieder, Ajay J Kirtane, et al.
Circulation|October 26, 2023
Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial ProgramMichel Azizi, Andrew S P Sharp, Naomi D L Fisher, et al.
Pageof 11